See the latest #CART #CellTherapy live event from PeerView #Tandem24 #MedEd api.lrn.peerview.com/psocial/share/…

Round 1: Haplo vs. Gene Therapy for Sickle Cell 🥊 #APPtrack #tandem2024 ⁦ASTCT⁩

Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Socie… pubmed.ncbi.nlm.nih.gov/37951502/

JUST OFF THE PRESS from NEJM #ASCO2023 ! We are SO proud of Ola Oluwole Vanderbilt-Ingram Cancer Center as co- author re: the role of #axicabtagene , an autologous anti-CD19 #CAR -T therapy for refrac large B-cell #lymphoma for EFS. CONGRATS!! #cancer research #cancer #hematology Vanderbilt University Medical Center

OS improved with Axicabtagene Ciloleucel vs ASCT in Large B-Cell Lymphoma - being presented today by Jason Westin, MD FACP #ASCO23 #CARTcells #lymsm #TcellRx Kite, a Gilead Company NEJM nejm.org/doi/full/10.10…

#NEWS : Announcing detailed results from the overall survival analysis of the landmark Phase 3 study of #CARTcell therapy compared with historical standard of care as initial treatment for relapsed/refractory large B-cell lymphoma. #ASCO23

Live from #EBMT23 . Thank you all for joining. What a great transplant community ⁦The EBMT⁩ ⁦The EBMT_Nurses⁩ ⁦IACH⁩

#NEWS : Today, we announced the primary overall survival (OS) analysis results, a key secondary endpoint, of our Phase 3 study of CAR T-cell therapy for initial treatment of relapsed/refractory large B-cell lymphoma.

Calling all #hematology #oncology providers! On 3/30 at 5pm CT, join Bipin Savani Professor of Medicine at Vanderbilt-Ingram Cancer Center for the IMPACT Malignant Hematology Webinar Series on Post-Transplant Supportive Care and #Survivorship . #cancerresearch
Register: impactSurvivorship.eventbrite.com

Axi-Cel Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma - ZUMA7 ⁦Kite, a Gilead Company⁩ #CARTcells #lymsm kitepharma.com/news/press-rel…

🎯🎉ASTCT #Tandem23

Our own Vivek ⁦⁦Vivek Patel, MD⁩ presenting important data that CRS is not essential for response in CAR therapy at the TCT conf. Go Vivek!

My awesome mentor Ola Oluwole chairing a session on moving CAR-T to the outpatient setting. Looking forward to improving patient quality of life #tandem23

VUMC Department of Medicine Vanderbilt-Ingram Cancer Center

Ola Oluwole It's our team's data, Ola. It takes a village for FULLY outpatient CAR/ALLO program Vanderbilt-Ingram Cancer Center Bipin Savani Adetola Kassim Indus BMT Group

our outstanding fellow Eden Biltibo soon to be exceptional faculty Vanderbilt Hem / Onc Vanderbilt-Ingram Cancer Center VUMC Department of Medicine

👏🏻👍 Great job!! Fantastic work!!! Vanderbilt-Ingram Cancer Center Vanderbilt Hem / Onc @VUMC_MD VUSM Basic Sciences VandyBiomed Vanderbilt Cell and Developmental Biology Vanderbilt Biochemistry #academictwitter #WomenInSTEM Ben Ho Park Dr. jordan berlin